Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Fetsund – page 46

607 clinical trials in Fetsund, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Fetsund at a glance
607
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

607 trials in Fetsund

Open in trial search

Study of Inotuzumab Ozogamicin Alone and with Drug Combination for Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Inotuzumab Ozogamicin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Study on Pyridoxine for Patients with Primary Sclerosing Cholangitis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pyridoxine Hydrochloride
  • Sponsor:Oslo University Hospital HF

Multiple sclerosis

Not recruiting

Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Natalizumab
  • Sponsor:Helse Bergen HF

Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Cervix carcinoma

Not recruiting

Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:Seagen Inc.

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.